BAXTER INTL INC's ticker is BAX and the CUSIP is 071813109. A total of 1,039 filers reported holding BAXTER INTL INC in Q1 2015. The put-call ratio across all filers is 0.65 and the average weighting 0.4%.
About BAXTER INTL INC
Baxter International Inc. is a global healthcare company that specializes in developing and manufacturing medical products and therapies. The company has a long history of innovation and has been at the forefront of developing life-saving treatments for patients around the world.
Baxter's product portfolio includes a wide range of medical devices, pharmaceuticals, and biotechnology products. The company's products are used in hospitals, clinics, and other healthcare settings to treat a variety of conditions, including hemophilia, immune disorders, kidney disease, and other chronic and acute medical conditions.
Baxter's commitment to innovation has helped the company maintain a strong position in the healthcare industry. The company invests heavily in research and development, and has a strong pipeline of new products in development.
Baxter's leadership team is also a key strength of the company. The CEO, José Almeida, has a strong track record of success in the healthcare industry, and has been instrumental in driving the company's growth and success.
Overall, Baxter International Inc. is a strong and innovative company that is well-positioned to continue delivering value to patients, healthcare providers, and investors alike. With a strong product portfolio, a commitment to innovation, and a talented leadership team, Baxter is a company that investors should keep an eye on in the years to come.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q2 2023 | $240,830 | +12.3% | 5,286 | 0.0% | 0.02% | +10.0% |
Q1 2023 | $214,400 | -20.2% | 5,286 | +0.3% | 0.02% | -20.0% |
Q4 2022 | $268,612 | -5.4% | 5,270 | 0.0% | 0.02% | -7.4% |
Q3 2022 | $284,000 | -16.0% | 5,270 | 0.0% | 0.03% | -10.0% |
Q2 2022 | $338,000 | -17.2% | 5,270 | 0.0% | 0.03% | -6.2% |
Q1 2022 | $408,000 | -9.7% | 5,270 | 0.0% | 0.03% | -5.9% |
Q4 2021 | $452,000 | +6.1% | 5,270 | -0.6% | 0.03% | 0.0% |
Q3 2021 | $426,000 | 0.0% | 5,300 | 0.0% | 0.03% | 0.0% |
Q2 2021 | $426,000 | -4.7% | 5,300 | 0.0% | 0.03% | -8.1% |
Q1 2021 | $447,000 | -7.1% | 5,300 | -11.7% | 0.04% | -15.9% |
Q4 2020 | $481,000 | -0.4% | 6,000 | 0.0% | 0.04% | -8.3% |
Q3 2020 | $483,000 | -6.4% | 6,000 | 0.0% | 0.05% | -9.4% |
Q2 2020 | $516,000 | +6.0% | 6,000 | 0.0% | 0.05% | -8.6% |
Q1 2020 | $487,000 | -4.7% | 6,000 | -1.9% | 0.06% | +20.8% |
Q4 2019 | $511,000 | -9.7% | 6,115 | -5.5% | 0.05% | -12.7% |
Q3 2019 | $566,000 | +7.6% | 6,470 | +0.8% | 0.06% | +5.8% |
Q2 2019 | $526,000 | -23.9% | 6,420 | -24.5% | 0.05% | -25.7% |
Q1 2019 | $691,000 | +62.2% | 8,498 | +31.2% | 0.07% | +45.8% |
Q4 2018 | $426,000 | -43.1% | 6,475 | -33.4% | 0.05% | -36.0% |
Q3 2018 | $749,000 | +2.0% | 9,720 | -2.2% | 0.08% | -12.8% |
Q2 2018 | $734,000 | -2.5% | 9,940 | -14.1% | 0.09% | +6.2% |
Q1 2018 | $753,000 | +24.7% | 11,576 | +23.9% | 0.08% | +22.7% |
Q4 2017 | $604,000 | +6.2% | 9,340 | +3.0% | 0.07% | +1.5% |
Q3 2017 | $569,000 | -19.3% | 9,065 | -22.1% | 0.06% | -20.7% |
Q2 2017 | $705,000 | +47.2% | 11,637 | +26.2% | 0.08% | +41.4% |
Q1 2017 | $479,000 | -11.5% | 9,220 | -24.4% | 0.06% | -19.4% |
Q4 2016 | $541,000 | -6.2% | 12,195 | +0.6% | 0.07% | +1.4% |
Q3 2016 | $577,000 | -11.4% | 12,124 | -15.7% | 0.07% | -15.5% |
Q2 2016 | $651,000 | +5.3% | 14,383 | -4.2% | 0.08% | 0.0% |
Q1 2016 | $618,000 | +2.5% | 15,019 | -5.1% | 0.08% | +1.2% |
Q4 2015 | $603,000 | +8.1% | 15,822 | -6.8% | 0.08% | +6.4% |
Q3 2015 | $558,000 | -45.2% | 16,969 | +16.6% | 0.08% | -42.6% |
Q2 2015 | $1,018,000 | +1.8% | 14,557 | -0.3% | 0.14% | +3.0% |
Q1 2015 | $1,000,000 | +7.4% | 14,605 | +15.0% | 0.13% | +3.9% |
Q4 2014 | $931,000 | -9.5% | 12,705 | -11.4% | 0.13% | -12.4% |
Q3 2014 | $1,029,000 | -27.0% | 14,338 | -26.4% | 0.14% | -9.4% |
Q2 2014 | $1,410,000 | -14.7% | 19,493 | -13.2% | 0.16% | -16.7% |
Q1 2014 | $1,653,000 | +37.8% | 22,463 | +30.2% | 0.19% | +35.2% |
Q4 2013 | $1,200,000 | +3.1% | 17,258 | -2.6% | 0.14% | -2.1% |
Q3 2013 | $1,164,000 | -4.9% | 17,715 | +0.2% | 0.14% | -8.8% |
Q2 2013 | $1,224,000 | – | 17,675 | – | 0.16% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Soditic Asset Management LLP | 147,620 | $7,951,000 | 9.91% |
NUANCE INVESTMENTS, LLC | 5,429,702 | $292,444,000 | 6.51% |
Endurant Capital Management LP | 245,093 | $13,201,000 | 4.30% |
Veritas Asset Management LLP | 8,589,401 | $462,625,000 | 3.83% |
GENERATION INVESTMENT MANAGEMENT LLP | 11,876,040 | $639,644,000 | 3.80% |
Sivik Global Healthcare LLC | 120,000 | $6,463,000 | 3.59% |
KINGDON CAPITAL MANAGEMENT, L.L.C. | 480,500 | $25,880,000 | 3.31% |
Integral Health Asset Management, LLC | 300,000 | $16,158,000 | 3.14% |
Boothe Investment Group, Inc. | 89,078 | $4,798,000 | 3.11% |
Glenview Capital Management | 2,257,019 | $121,563,000 | 3.04% |